中国新药与临床杂志2024,Vol.43Issue(6) :426-431.DOI:10.14109/j.cnki.xyylc.2024.06.06

托珠单抗在儿童风湿免疫性疾病中应用的安全性研究

Safety of tocilizumab in children with rheumatic immune disease

刘红霞 谢婷 朱彦 谭波宇 杨巧玲 郝胜
中国新药与临床杂志2024,Vol.43Issue(6) :426-431.DOI:10.14109/j.cnki.xyylc.2024.06.06

托珠单抗在儿童风湿免疫性疾病中应用的安全性研究

Safety of tocilizumab in children with rheumatic immune disease

刘红霞 1谢婷 1朱彦 1谭波宇 1杨巧玲 1郝胜2
扫码查看

作者信息

  • 1. 上海市儿童医院/上海交通大学医学院附属儿童医院 药学部,上海 200062
  • 2. 上海市儿童医院/上海交通大学医学院附属儿童医院肾脏风湿免疫科,上海 200062
  • 折叠

摘要

目的 分析托珠单抗在儿童风湿免疫性疾病中应用的安全性,为临床用药提供参考.方法 收集2016年1月1日—2022年8月9日使用托珠单抗治疗风湿免疫性疾病患儿的临床资料,对不良事件(AE)的发生率及影响因素、分布、发生时间和转归等进行回顾性分析.结果 共纳入53例使用托珠单抗治疗的患儿,全身型幼年特发性关节炎48例、干燥综合征1例、自身免疫疾病(自身炎症性疾病)2例、幼年特发性关节炎(多关节型)1例.多发性大动脉炎1例,AE发生率为87%(46/53),主要AE为高甘油三酯血症(60%)、肝损伤(49%)、高胆固醇血症(30%)、高胆红素血症(8%)、中性粒细胞减少(9%)、超敏反应(8%)等.导致停药的主要AE为超敏反应,高胆固醇血症的发生与更高的给药剂量相关,肝损伤的发生与更高年龄和更高体重指数相关.AE大部分较轻,可自行恢复正常,持续用药率96%(44/46).结论 儿童使用托珠单抗治疗后相关AE发生率较高,超敏反应可导致停药,用药期间需要予以关注.虽然大部分患儿只发生轻度肝损伤,仍需警惕严重肝衰竭的发生可能.

Abstract

AIM To analyze the safety of tocilizumab in children with rheumatic immune disease and provide reference for clinical medication.METHODS The medical records of tocilizumab from January 1st,2016 to August 9th,2022 through the medical record system were collected.Retrospective analysis of the adverse events(AE)incidence and influencing factors,distribution,occurrence time,and outcome.RESULTS A total of 53 children treated with tocilizumab were included,48 cases of systemic juvenile idiopathic arthritis,1 case of Sjogren's syndrome,2 cases of autoimmune disease(autoimmune disease),1 case of juvenile idiopathic arthritis(polyarticular type),and 1 case of multiple arteritis.The incidence of AE was 87%(46/53).The main AE were hypertriglyceridemia(60%),liver injury(49%),hypercholesterolemia(30%),hyperbilirubinemia(8%),neutropenia(9%),hypersensitivity(8%).Hypersensitivity was the main AE leading to drug withdrawal.The occurrence of hypercholesterolemia was associated with higher dose,and the occurrence of liver injury was associated with higher age and higher body mass index.Most of AE were mild and could recover to normal without treatment,and continuous medication rate was 96%(44/46).CONCLUSION The incidence of AE related to the use of tocilizumab in children is high.Hypersensitivity reactions may lead to drug withdrawal,and attention should be paid during the medication period.Although most children only suffer from mild liver injury,it is still necessary to be alert to the possibility of severe liver failure.

关键词

托珠单抗/安全/血脂异常/化学性与药物性肝损伤/自身免疫疾病/超敏反应

Key words

tocilizumab/safety/dyslipidemias/chemical and drug induced liver injury/autoimmune diseases/hypersensitivity

引用本文复制引用

基金项目

上海市"医苑新星"青年医学人才培养资助计划(沪卫人事[2020]87号)

出版年

2024
中国新药与临床杂志
中国药学会 上海市食品药品监督管理局科技情报研究所

中国新药与临床杂志

CSTPCD北大核心
影响因子:0.967
ISSN:1007-7669
参考文献量4
段落导航相关论文